Artelo Biosciences Past Earnings Performance
Past criteria checks 0/6
Artelo Biosciences's earnings have been declining at an average annual rate of -19.6%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually.
Key information
-19.6%
Earnings growth rate
42.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -143.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Artelo jumps 21% as publication highlights pre-clinical data on drug platform
Aug 16Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
Mar 28
Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
Mar 09Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Nov 02Relief For Cancer Patients In Artelo Bioscience Pipeline
Jul 12Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
May 20Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Feb 04INO, VXRT, BTU and TTM among premarket gainers
Feb 02Artelo Biosciences EPS misses by $0.04
Jan 14Artelo Biosciences on go with cancer appetite recovery study
Nov 16Revenue & Expenses Breakdown
How Artelo Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 4 | 6 |
| 30 Jun 24 | 0 | -10 | 4 | 7 |
| 31 Mar 24 | 0 | -10 | 4 | 6 |
| 31 Dec 23 | 0 | -9 | 4 | 6 |
| 30 Sep 23 | 0 | -10 | 5 | 5 |
| 30 Jun 23 | 0 | -9 | 5 | 5 |
| 31 Mar 23 | 0 | -10 | 6 | 5 |
| 31 Dec 22 | 0 | -10 | 6 | 4 |
| 30 Sep 22 | 0 | -13 | 7 | 6 |
| 30 Jun 22 | 0 | -13 | 7 | 6 |
| 31 Mar 22 | 0 | -12 | 6 | 6 |
| 31 Dec 21 | 0 | -12 | 6 | 6 |
| 30 Nov 21 | 0 | -9 | 5 | 4 |
| 31 Aug 21 | 0 | -7 | 5 | 3 |
| 31 May 21 | 0 | -7 | 4 | 2 |
| 28 Feb 21 | 0 | -5 | 3 | 2 |
| 30 Nov 20 | 0 | -5 | 3 | 2 |
| 31 Aug 20 | 0 | -5 | 3 | 2 |
| 31 May 20 | 0 | -4 | 3 | 2 |
| 29 Feb 20 | 0 | -4 | 3 | 2 |
| 30 Nov 19 | 0 | -3 | 2 | 2 |
| 31 Aug 19 | 0 | -2 | 2 | 1 |
| 31 May 19 | 0 | -2 | 2 | 1 |
| 28 Feb 19 | 0 | -2 | 1 | 1 |
| 30 Nov 18 | 0 | -3 | 1 | 1 |
| 31 Aug 18 | 0 | -2 | 1 | 1 |
| 31 May 18 | 0 | -2 | 1 | 1 |
| 28 Feb 18 | 0 | -1 | 1 | 1 |
| 30 Nov 17 | 0 | -1 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
| 30 Nov 15 | 0 | 0 | 0 | 0 |
| 31 Aug 15 | 0 | 0 | 0 | 0 |
| 31 May 15 | 0 | 0 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
| 30 Nov 14 | 0 | 0 | 0 | 0 |
Quality Earnings: ARTL is currently unprofitable.
Growing Profit Margin: ARTL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARTL is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare ARTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (54.6%).
Return on Equity
High ROE: ARTL has a negative Return on Equity (-143.39%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 08:26 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Artelo Biosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Vernon Bernardino | H.C. Wainwright & Co. |
| Matthew Kaplan | Ladenburg Thalmann & Company |